abs218.txt	in	desmoplastic	melanoma		tumor	cells	and	tumor-associated	fibroblasts	are	themajor	dominators	playing	a	critical	role	in	the	fibrosis	morphology	as	well	asthe	immunosuppressive	tumor	microenvironment	(tme)		compromising	the	efficacy	oftherapeutic	options		to	overcome	this	therapeutic	hurdle		we	developed	aninnovative	chemo-immunostrategy	based	on	targeted	delivery	of	mitoxantrone	(mit)and	celastrol	(cel)		two	potent	medicines	screened	and	selected	with	the	bestanticancer	and	antifibrosis	potentials		importantly		cel	worked	in	synergy	withmit	to	induce	immunogenic	tumor	cell	death		here		we	show	that	when	effectivelyco-delivered	to	the	tumor	site	at	their	optimal	ratio	by	a	tme-responsivenanocarrier		the	5	1	combination	of	mit	and	cel	significantly	triggeredimmunogenic	tumor	apoptosis	and	recovered	tumor	antigen	recognition		thuseliciting	overall	antitumor	immunity		furthermore		the	strong	synergy	benefittedthe	host	in	reduced	drug	exposure	and	side	effects		collectively		thenanocarrier-mediated	chemo-immunotherapy	successfully	remodeled	fibrotic	andimmunosuppressive	tme		arrested	cancer	progression		and	further	inhibited	tumormetastasis	to	major	organs		the	affected	tumors	remained	dormant	long	afterdosing	stopped		resulting	in	a	prolonged	progression-free	survival	and	sustainedimmune	surveillance	of	the	host	bearing	desmoplastic	melanoma	
